Evaluating Treatment Effect Based on Duration of Response for a Comparative Oncology Study-Reference-Cited by-同舟云学术

Evaluating Treatment Effect Based on Duration of Response for a Comparative Oncology Study

Published:2018-06-01 Issue:6 Volume:4 Page:874
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Huang Bo¹,Tian Lu²,Talukder Enayet¹,Rothenberg Mace³,Kim Dae Hyun⁴,Wei Lee-Jen⁵

Affiliation:

1. Pfizer Inc, Groton, Connecticut

2. Stanford Medical School, Stanford University, Stanford, California

3. Pfizer Inc, New York, New York

4. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

5. Department of Biostatistics, Harvard University, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Reference6 articles.

1. Analysis of duration of response in oncology trials.;Ellis;Contemp Clin Trials,2008

2. First-line crizotinib versus chemotherapy in ALK-positive lung cancer.;Solomon;N Engl J Med,2014

3. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.;Uno;J Clin Oncol,2014

4. Interpretability of cancer clinical trial results using restricted mean survival time as an alternative to the hazard ratio;Pak;JAMA Oncol,2017

5. US Food and Drug Administration. Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. Washington, DC, US Food and Drug Administration. 2007 May:1-9. https://www.fda.gov/downloads/Drugs/Guidances/ucm071590.pdf. Accessed January 8, 2018.

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lazertinib in EGFR-Variant Non–Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors;JAMA Oncology;2024-08-15

2. Inferences for the distribution of the duration of response in a comparative clinical study;Clinical Trials;2024-08-08

3. Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial;European Urology;2024-08

4. Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study;The Lancet Oncology;2024-07

5. Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma;JAMA Oncology;2024-05-01